Alyeska Investment Group
MRKR icon

Alyeska Investment Group’s Marker Therapeutics MRKR Stock Holding History

Alyeska Investment Group’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-213,020
Closed -$326K – 676
2025
Q2 		$326K Sell
213,020
-48,757
-19% -$62.6K ﹤0.01% 531
2025
Q1 		$322K Sell
261,777
-653,814
-71% -$1.2M ﹤0.01% 480
2024
Q4 		$38.5M Buy
+915,591
New +$3.24M 0.14% 176

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $239M AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Alyeska Investment Group's MRKR Position: Q3 2025 in Review

Alyeska Investment Group sold out of Marker Therapeutics (MRKR) in Q3 2025, closing a stake of 213,020 shares — an estimated $326K sold.

Alyeska Investment Group first reported a position in MRKR in Q4 2024 and held it in 3 quarters. The position peaked at $38.5M in Q4 2024. 32 funds tracked by Wall St. Rank hold MRKR as of Q3 2025.

  • Alyeska Investment Group reported no remaining Marker Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 213,020 Marker Therapeutics shares in Q3 2025, an estimated $326K.
  • Alyeska Investment Group first reported a position in Marker Therapeutics in Q4 2024 and held it in 3 quarters.
  • Alyeska Investment Group's Marker Therapeutics position peaked at $38.5M in Q4 2024.
  • 32 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2025.

Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.